Evofem Biosciences

Evofem Biosciences partners with UAE-based Pharma 1 to expand access to FDA-approved SOLOSEC® (secnidazole) for bacterial vaginosis and trichomoniasis in the Middle East. The agreement grants Pharma 1 exclusive commercialization rights, with plans to file for UAE regulatory approval by mid-2025. Evofem will supply SOLOSEC at cost-plus pricing, leveraging Pharma 1’s distribution network. Targeting a region with high BV prevalence (25%–41% in MENA), the single-dose therapy addresses compliance challenges linked to multi-day treatments. The deal aligns with Evofem’s global expansion strategy, building on prior collaborations for its contraceptive PHEXXI®, and aims to reduce health risks like HIV transmission and preterm births in underserved populations.